Compare Inovio Pharmaceuticals Inc (INO) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Vale SA — how do they compare? Inovio Pharmaceuticals Inc trades at $1.1 (market cap $119.42M), while Vale SA trades at $13.5 (market cap $58.70B). The key difference: Vale SA is far larger — about 491.5× Inovio Pharmaceuticals Inc's market cap, and Vale SA pays a 8.75% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Vale SA for 109 Days on average.
| INO | VALE | |
|---|---|---|
Market Cap | $119.42M | $58.70B |
Volume | 2,789,649 | 45,073,516 |
Sector | Health | Basic Materials |
52-Week High | $2.65 | $17.82 |
52-Week Low | $0.66 | $10.75 |
Typical Hold Time | 43 Days | 109 Days |
Enterprise Value | $90.75M | $74.94B |
Dividend Yield | — | 8.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.09, down 3.54% on the day, with a bearish technical signal driven by moving averages. The company reported a net loss of $84.95 million in 2025 on minimal revenue of $65,340, with negative profitability metrics, but has beaten EPS estimates in recent quarters. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107.
The investment case hinges on regulatory approval of INO-3107, with a consensus price target of $2.75 implying significant upside. However, extreme financial losses, high cash burn, and dependence on dilutive financing pose substantial risks. Analyst sentiment is cautiously optimistic but reflects high uncertainty.
VALE trades at $13.61, down 3.34% amid broader market weakness in mining stocks. The stock shows bearish technical signals with recent earnings misses and declining profit margins (5.11% net margin in 2025). Revenue has stabilized around $38-41B, but iron ore pricing pressure and rising costs challenge near-term profitability. Analyst consensus remains mixed with 32% buy ratings despite a $16.21 price target suggesting 19% upside potential.
The investment case balances Vale's position as a low-cost iron ore producer against cyclical commodity exposure and Brazilian regulatory risks. Base metals growth provides diversification, but margin compression and debt increases warrant caution. Current valuation at 27x P/E appears stretched given earnings volatility, making risk-reward balanced for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
